Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report) and Monte Rosa Therapeutics (GLUE – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Apellis Pharmaceuticals (APLS)
In a report released today, Lachlan Hanbury Brown from William Blair maintained a Buy rating on Apellis Pharmaceuticals. The company’s shares closed last Tuesday at $22.21.
According to TipRanks.com, Brown is a 4-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $31.69, which is a 50.0% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
Monte Rosa Therapeutics (GLUE)
In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Monte Rosa Therapeutics. The company’s shares closed last Tuesday at $19.40.
According to TipRanks.com, McCammon is a 5-star analyst with an average return of
Currently, the analyst consensus on Monte Rosa Therapeutics is a Strong Buy with an average price target of $33.80.
